Global Insulin Glargine Market Industry Overview and Forecast to 2031 – Market Analysis and Market Share

Global Insulin Glargine Market - Industry Overview

The global insulin glargine market is experiencing significant growth, fueled by the escalating incidence of diabetes, especially type 2 diabetes, which accounts for about 90-95% of all diabetes cases. Insulin Glargine, a long-acting insulin analog, is designed to provide a stable, 24-hour basal insulin level with a once-daily injection, which simplifies diabetes management and enhances patient adherence. This convenience not only improves patient adherence but also enhances overall treatment outcomes, making Insulin Glargine a preferred choice among healthcare providers and patients alike.

Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.

Global Insulin Glargine Market – Market Analysis and Market Size

The market's expansion is further propelled by Insulin Glargine's ability to reduce the risk of hypoglycemia, a common serious side effect associated with other insulin therapies. Such predictable pharmacokinetic profile has made it a cornerstone in the treatment of diabetes, contributing to its widespread adoption and driving market growth. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Insulin Glargine Market is increasing at a CAGR of 6.70%. Our detailed analysis forecasts that the market is valued at USD 6.56 billion in 2023 and is expected to grow upto USD 11.03 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Insulin Glargine Market – Market Dynamics

Global Insulin Glargine Market Growth Drivers

Rising cases of Type-2 diabetes

According to the IDF Diabetes Atlas, 537 million adults (1 in 10) were living with diabetes in 2021, with this number expected to rise to 643 million by 2030 and 783 million by 2045. The anticipated surge in diabetes cases underscores the critical need for advanced insulin therapies, positioning Insulin Glargine as a key driver in the market's expansion.

Rising geriatric population

According to the World Health Organization (WHO), by 2050, the global population of people aged 60 years and older is expected to double, reaching 2.1 billion. As the elderly population grows, so does the prevalence of age-related conditions, including type 2 diabetes, which is more common among older adults. The need for effective diabetes management solutions in this age group is critical, and Insulin Glargine, with its stable, long-acting glucose control and once-daily dosing, is particularly well-suited for older patients. Growing demand for tailored insulin therapies among the aging population is propelling the Global Insulin Glargine market growth.

Global Insulin Glargine Market Growth Opportunities

Increasing Government Initiatives and Healthcare Policies

Emerging markets such as India, Brazil, and China have witnessed a significant investment in healthcare infrastructure. For Instance, India’s government launched the Ayushman Bharat scheme, aimed at providing healthcare services to over 500 million people, particularly in rural and underserved areas. This scheme includes the establishment of thousands of Health and Wellness Centers across the country, many of which are equipped to manage chronic diseases like diabetes consequently, fostering the Global Insulin Glargine Market Growth.

Development of Biosimilars

The development and approval of biosimilar versions of insulin glargine represents a substantial growth opportunity for the Global Insulin Glargine Market, particularly in price-sensitive regions. Eli Lilly and Boehringer Ingelheim developed Basaglar, a biosimilar to insulin glargine. Basaglar was among the first insulin glargine biosimilars approved by both the FDA in the United States and the European Medicines Agency (EMA) in Europe. Its approval represented a crucial step in making insulin glargine more affordable and accessible.

Global Insulin Glargine Market Growth Challenges

Complex Manufacturing Process

Insulin glargine, like other biologics, necessitates a complicated and sophisticated production procedure. Production requires advanced biotechnological processes, tight quality control, and adherence to regulatory norms, all of which contribute to high production costs. These expenses may limit the affordability of insulin glargine, particularly in low-income areas, limiting Global Insulin Glargine Market expansion.

Supply Chain Disruptions

During the 2022 global semiconductor shortage insulin manufacturers faced delays in production and distribution. The shortage of key components used in the production of insulin delivery devices, like insulin pumps and pens, led to reduced availability of insulin glargine for patients. Geopolitical tensions, such as the trade restrictions imposed during the U.S.-China trade war, further complicated logistics and import-export processes, exacerbating shortages and increasing costs for insulin glargine. Such disruptions not only exacerbated shortages but also increased costs, underscoring how vulnerabilities in the supply chain can impede Global Insulin Glargine Market growth.

Global Insulin Glargine Market Restraints

Regulatory and Reimbursement Challenges

In the Global Insulin Glargine (PPD) market, approval delays are a major regulatory constraint that are frequently caused by the drawn-out and intricate procedures mandated by organizations such as the FDA and EMA. For instance, it took several years for the first drug licensed particularly for PPD, brexanolone (Zulresso), to get approval. The entire process from first proposal to approval took almost ten years, despite the breakthrough status, showing how regulatory obstacles can cause delays in the availability of novel medications. Such Delays hamper the introduction of novel medicines, which can hinder the Global Insulin Glargine Market expansion.

Global Insulin Glargine Market Scope and Trends

• The combination of insulin icodec and semaglutide has shown promising results in managing type 2 diabetes by effectively reducing HbA1c levels and body weight. Insulin icodec, a novel long-acting insulin with a once-weekly dosing regimen, provides sustained glycemic control, while semaglutide, a GLP-1 receptor agonist, enhances glucose-dependent insulin secretion and suppresses appetite.
• Sanofi launches an anti-diabetic medication in India. Soliqua is a once-daily injectable combination medicine that includes insulin glargine 100 Units/ml, a long-acting basal insulin, and lixisenatide, a GLP-1 receptor agonist.

Global Insulin Glargine Market Regional Analysis – Market Trends

Key Insights

• In North America, The U.S. and Canada have a well-established market for insulin glargine, driven by high diabetes prevalence and advanced healthcare systems. The U.S. market is particularly strong due to extensive insurance coverage and high patient demand.
• The European market shows strong performance, particularly in Western Europe, with countries like Germany and France leading in insulin glargine adoption. The region’s well-established healthcare systems and favorable reimbursement frameworks facilitate widespread access. Additionally, initiatives to improve diabetes care in Eastern and Southern Europe are expected to boost market growth.
• The Asia Pacific region presents tremendous growth opportunities, with China and India at the forefront. In China, expanding healthcare coverage and increasing public health initiatives are driving market expansion, while India’s burgeoning healthcare sector and rising diabetes awareness offer significant growth potential. The increasing focus on diabetes management in countries like Japan and South Korea also contributes to a positive market outlook.
• Optimistic growth prospects are evident in the Middle East and parts of Africa. Countries like Saudi Arabia and South Africa are expanding their healthcare infrastructure and diabetes management programs, creating a favorable environment for insulin glargine. Continued investments in healthcare and increasing public health initiatives are expected to accelerate market development in these regions.

Global Insulin Glargine Market Leading Players

• Biocon (India)
• Sanofi-Aventis (France)
• Novo Nordisk A/S (Denmark)
• Lilly (U.S.)
• LGM Pharma (U.S.)
• Trumac Healthcare (India)
• Gan & Lee Pharmaceuticals (China)
• ADOCIA (France)
• Lupin Ltd (India)
• WOCKHARDT (India)
• Cipla Inc. (India)
• Pfizer Inc. (U.S.)
• Biogenomics Limited (India)
• Loka Biosciences (India)
• Amigoz Lifesciences (India)
• Endocrine Technologies, Inc. (U.S.)
• Alfa Chemical Corp. (India)
• Accurate Chemical & Scientific Corporation (U.S.)
• Spectrum Chemical Mfg. Corp. (India)
• Sekisui Diagnostics LLC (U.S.)

 Global Insulin Glargine Market Recent Developments

• In January 2024, A study conducted by the Doctors of India Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals discovered that two doses of insulin (basal insulin analog), while higher in dose, are marginally better than a single shot (premixed insulin) in decreasing HbA1c (glycated haemoglobin). The study's findings highlighted the need of initiating insulin therapy on time.
• In June, 2024 Geropharm, a Russian company, has started delivering insulin products to Morocco. The first shipment of 97 thousand syringe pens containing long-acting insulin glargine has already left for the country. The deal with Morocco for the provision of insulin was extended until 2026.
• In March 2023, Eli Lilly and Company announced a 70% price decrease for its most widely prescribed insulins, as well as an expansion of its Insulin Value Program, which limits patients' out-of-pocket expenditures to $35 or less per month. Lilly is taking these steps to make Lilly insulin more accessible and to assist Americans who may struggle to navigate a complex healthcare system and so be unable to obtain inexpensive insulin.

SKU-59051